Financial assistance was provided in the form of a capital investment, according to the Commission.
In a setback for pharmaceutical giant Bayer, the late-stage study on its new product Verquvo (Vericiguat) did not meet its primary endpoint in a well-controlled patient population with heart failure with reduced ejection fraction (HFrEF) without a recent heart failure event. The Phase-3 study was conducted by Bayer before being presented at the European Society of Cardiology (ESC) Congress 2025.
The disappointing data on Verquvo was one of the key highlights of the ESC Congress 2025. However, it seems that the market potential of other Bayer products, such as Nubeqa and Kerendia, has been capturing more attention lately. Leverkusen recently reported strong gains for these drugs.
The results of the Phase-3 VICTOR study for Verquvo were simultaneously published in the prestigious medical journal, The Lancet. Despite the setback, Bayer maintains that the positive benefit-risk profile of Vericiguat in its approved indication for patients with HFrEF following a recent heart failure event remains unchanged based on the pivotal Phase-3 VICTORIA study.
The news of the failed trial initially sent Bayer's shares trading at the bottom of the German benchmark index. However, as of the start of September 2025, the shares have experienced slight losses, reflecting the broader market trends rather than specific company performance.
As Bayer continues to evaluate the data from the VICTOR study and explore potential future directions for Verquvo, investors and the medical community will be closely watching for any developments. The company's commitment to delivering innovative treatments for cardiovascular diseases remains unwavering, and the focus now shifts to other promising compounds in its pipeline.
Read also:
- Nightly sweat episodes linked to GERD: Crucial insights explained
- Antitussives: List of Examples, Functions, Adverse Reactions, and Additional Details
- Asthma Diagnosis: Exploring FeNO Tests and Related Treatments
- Unfortunate Financial Disarray for a Family from California After an Expensive Emergency Room Visit with Their Burned Infant
